Fred Hutch is conducting a number of therapeutic and non-therapeutic COVID-19 studies including treatment trials, observational studies and vaccine trials. To end this pandemic, we need volunteers of all ages, races, ethnicities and backgrounds to participate in research studies. That includes volunteers who have had a COVID-19 diagnosis and those who have never had a COVID-19 diagnosis.
The following studies and trials are currently enrolling participants. Participants may be eligible to enroll in certain studies concurrently. If you are unsure, please contact us to learn more.
Participants in observational studies may provide researchers with data and information through questionnaires, medical exams or other tests.
Fred Hutch researchers are conducting observational studies of people who are at risk for or have been diagnosed with COVID-19. These studies may observe the effect of a risk factor, a diagnostic test, a treatment or other interventions. The data collected can help advance understanding of how the disease progresses as well as its causes.
Participants in observational studies may provide researchers with data and information through questionnaires, medical exams or other tests.
Stopping the COVID-19 pandemic requires a better understanding of how the disease spreads. The SCAN study provides free at-home testing for COVID-19. The findings will help the research partners, including Public Health — Seattle & King County, to keep people informed and make data-driven decisions on how to protect the community.
Fred Hutch's Dr. Julie McElrath is leading the Seattle COVID Cohort Study, an observational study, focusing on individuals who have confirmed COVID-positive results from the last 30 days. This study will help us gain an understanding of how the immune system works in response to COVID, and enable us to find better ways to prevent and treat the virus.”
The Flu Study research team, in partnership with Fred Hutch, is looking for participants for a research study about immunity to respiratory illnesses like COVID-19 and influenza.
Participants in the study will give blood samples at three different points in the study. They will also answer weekly surveys about their health, and if they experience respiratory illness symptoms, complete a nasal swab to test for COVID-19. This study will contribute to the growing body of research to better understand immune systems responses to respiratory illnesses.
Fred Hutch is working with the National Institutes of Health and others to design human clinical trials for the most promising vaccine candidates developed by industry partners. These candidates must pass three phases of human testing to ensure they are safe and effective in preventing a disease. Typically, a vaccine is tested on healthy individuals.
Participants in a vaccine trial can expect to be carefully evaluated prior to receiving a vaccine and then closely monitored.
Fred Hutch is the operations center for the nationwide COVID-19 Prevention Trials Network (CoVPN). The CoVPN is conducting Phase 3 vaccine studies and is currently recruiting participants from across the U.S. to join the studies.
Fred Hutch researchers developing guidelines to help physicians with the diagnosis and management of COVID-19 in hematopoietic and cellular therapy patients, and continue to develop best practices for managing cancer care during the COVID-19 pandemic. These efforts include developing and implementing infection and environmental control policies, coordinating institution-wide efforts, outpatient considerations, treatment decisions, ethical considerations, hospital management of oncology patients, and employee and leadership well-being.
Fred Hutch is an important part of the international scientific response to the pandemic — tracking and modeling the virus' spread, developing diagnostic tests, designing vaccine trials, and working to prevent future outbreaks.
Our scientists are applying decades of expertise in the laboratory for solving disease problems and the development of new prevention and treatment options.
Our researchers are working to develop a safe and effective vaccine for COVID-19. The process involves intense laboratory efforts and testing.